Sachin D. Patel Acquires 24.97 Lakh Shares of Gujarat Themis Biosyn
Sachin D. Patel acquired 24,97,190 equity shares of Gujarat Themis Biosyn Limited for ₹400.45 per share on June 30, 2026. This inter-se transfer among promoters increases Patel's stake to 2.29% and is made under SEBI Takeover Regulations exemption.
The acquisition involves a significant number of shares and a change in shareholding percentages among the promoter group. While it is an inter-se transfer and does not trigger an open offer, it does alter the ownership structure within the promoter base, which can have medium-term implications.
The announcement details a share acquisition under existing regulations and exemptions, which is a routine corporate action within promoter groups. It does not inherently indicate a positive or negative change in the company's performance or outlook.
Sachin D. Patel has acquired 24,97,190 equity shares of Gujarat Themis Biosyn Limited, representing 2.29% of the company's diluted share capital. The acquisition, which took place on June 30, 2026, was executed at a price of ₹400.45 per share. This transaction is classified as an inter-se transfer among the Promoter and Promoter Group.
The acquirer, Sachin D. Patel, is availing an exemption under Regulation 10(1)(a)(i) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the transfer is between immediate relatives of the Promoters. Prior intimation of this inter-se transfer was made on June 23, 2026, and the required disclosure under Regulation 10(5) was filed with the stock exchanges four working days prior to the transaction.
Following the acquisition, Sachin D. Patel's shareholding in Gujarat Themis Biosyn Limited increased to 24,97,200 shares (2.29% of total share capital). Consequently, Themis Medicare Limited's shareholding decreased to 2,27,74,847 shares (20.90% of total share capital). The disclosure was made to BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.